MX2011011376A - Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. - Google Patents

Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.

Info

Publication number
MX2011011376A
MX2011011376A MX2011011376A MX2011011376A MX2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A
Authority
MX
Mexico
Prior art keywords
treatment
pathologic disorder
disorder
prophylaxis
lps
Prior art date
Application number
MX2011011376A
Other languages
English (en)
Inventor
Yaron Ilan
Gadi Lalazar
Tomer Adar
Meir Mizrahi
Ami Ben-Ya Acov
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of MX2011011376A publication Critical patent/MX2011011376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se refiere al uso de preparaciones enriquecidas con anticuerpos anti LPS, tal como los derivados de calostro de mamífero o huevos aviar, y opcionalmente anticuerpos adicionales contra antígenos, calostros, leche o componentes de productos de leche asociados con enfermedad, y cualesquiera adyuvantes para tratar, retardar o prevenir el progreso de un trastorno patológico, tal como enfermedad de hígado crónica, cirrosis y cualquier complicación o trastorno asociado con el mismo. La presente invención se refiere además a composiciones combinadas que comprenden una combinación de preparaciones de anticuerpo enriquecidas con anti-LPS de anticuerpos que reconocen al menos un antígeno específico para un trastorno patológico y usos del mismo en el tratamiento de trastornos relacionados con inmunidad.
MX2011011376A 2009-04-27 2010-04-27 Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. MX2011011376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17292209P 2009-04-27 2009-04-27
PCT/IL2010/000339 WO2010125565A2 (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Publications (1)

Publication Number Publication Date
MX2011011376A true MX2011011376A (es) 2012-04-20

Family

ID=42357536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011376A MX2011011376A (es) 2009-04-27 2010-04-27 Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.

Country Status (14)

Country Link
US (2) US10117930B2 (es)
EP (2) EP3461840A1 (es)
JP (1) JP5740390B2 (es)
KR (1) KR101785120B1 (es)
AU (1) AU2010243205B2 (es)
BR (1) BRPI1014774A2 (es)
CA (2) CA2760096C (es)
DK (1) DK2424890T3 (es)
EA (1) EA024697B1 (es)
ES (1) ES2684696T3 (es)
IL (1) IL215924B (es)
MX (1) MX2011011376A (es)
SG (1) SG175142A1 (es)
WO (1) WO2010125565A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943597B2 (en) 2010-08-17 2018-04-17 Immuron Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
CA2813612A1 (en) * 2010-10-04 2012-04-12 Immuron Limited Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
MX340019B (es) 2010-11-23 2016-06-22 Pantheryx Inc Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas.
DE102011006781A1 (de) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2012149405A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for regulating innate immune responses
AU2012269740A1 (en) * 2011-06-17 2013-01-31 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
WO2013189544A1 (en) * 2012-06-21 2013-12-27 Synthon B.V. Method of purifying an antibody
WO2014111516A1 (en) 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
ES2842206T3 (es) 2013-05-03 2021-07-13 Selecta Biosciences Inc Métodos y composiciones para potenciar linfocitos T reguladores CD4+
WO2015063693A1 (en) * 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
EA201790533A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов
EP3452064A4 (en) * 2016-05-06 2019-11-27 Hadasit Medical Research Services And Development COLOSTRUM HYPERIMMUN FOR USE IN MODULATING AND TREATING MAMMALIAN MICROBIOMA-ASSOCIATED DISORDERS
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法
WO2020010161A1 (en) * 2018-07-02 2020-01-09 Pure Tech Health Llc Milk vesicles for use in delivering biological agents
JP2022513337A (ja) * 2018-10-03 2022-02-07 アヌビス バイオ コーポレーション 動物の腸管感染症及び急性下痢を治療する組成物及び方法
BR112021010916A2 (pt) * 2018-12-05 2021-08-24 Viking Therapeutics, Inc. Composições e métodos para tratamento de distúrbios hepáticos
MX2021011445A (es) 2019-03-18 2021-10-13 Janssen Pharmaceuticals Inc Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos.
WO2021168321A1 (en) * 2020-02-19 2021-08-26 Anubis Bio Corporation Composition and methods for treating infectious agents using pathogen-specific antibodies
MX2023012232A (es) * 2021-04-16 2023-11-22 Prodigy Biotech Ovoproducto hiperinmunizado para tratar o prevenir la enfermedad hepatica alcoholica y la enfermedad de injerto contra huesped.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
JPS58154513A (ja) 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho 予防及び治療薬
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
WO1995008562A1 (en) 1993-09-20 1995-03-30 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
DE4337654C2 (de) 1993-11-04 1996-08-08 Biotest Pharma Gmbh Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat
IL139339A0 (en) 1998-05-27 2001-11-25 Gemma Biotechnology Ltd The induction of antibiotic peptides by lait (scd14) protein
DE19830607C2 (de) 1998-07-09 2002-08-01 Hte Ag The High Throughput Exp Verfahren zum Nachweis eines Produktes im Abstrom eines katalytischen Materials einer Vielzahl von katalytischen Materialien
CN100571715C (zh) 2002-03-21 2009-12-23 阿纳迪斯有限公司 含有生物活性物质的组合物及其制备和处理方法
WO2003097094A1 (en) 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
US9701737B2 (en) 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
US20070207187A1 (en) * 2004-09-29 2007-09-06 Mizuo Yajima Functional Composition Or Food Comprising Whey Protein, Antibody Derived From Milk Or Antibody
US20090169566A1 (en) 2004-11-22 2009-07-02 Anadis Ltd. Bioactive compositions
NZ575918A (en) * 2006-08-31 2012-03-30 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products
EP2268669B1 (en) 2008-03-13 2017-10-18 Immuron Limited Bovine Colostrum comprising anti-insulin antibodies for treating Metabolic Disorder diseases.
US9943597B2 (en) 2010-08-17 2018-04-17 Immuron Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Also Published As

Publication number Publication date
KR20120061067A (ko) 2012-06-12
WO2010125565A3 (en) 2011-01-27
ES2684696T3 (es) 2018-10-04
IL215924B (en) 2018-01-31
CA2760096A1 (en) 2010-11-04
IL215924A0 (en) 2011-12-29
EP2424890A2 (en) 2012-03-07
EP2424890B1 (en) 2018-08-01
US10117930B2 (en) 2018-11-06
SG175142A1 (en) 2011-12-29
CA2760096C (en) 2018-10-30
DK2424890T3 (en) 2018-09-17
CA3017477A1 (en) 2010-11-04
EA201171304A1 (ru) 2012-06-29
AU2010243205B2 (en) 2014-09-11
EA024697B1 (ru) 2016-10-31
JP5740390B2 (ja) 2015-06-24
BRPI1014774A2 (pt) 2019-04-16
WO2010125565A2 (en) 2010-11-04
US20120135007A1 (en) 2012-05-31
KR101785120B1 (ko) 2017-10-12
AU2010243205A1 (en) 2011-12-01
JP2012525376A (ja) 2012-10-22
US20190209681A1 (en) 2019-07-11
EP3461840A1 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
MX2011011376A (es) Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201892793A1 (ru) Анти-hla-g специфические антитела
WO2008033966A3 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EA036814B9 (ru) Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
BR112014008764A2 (pt) composições para o tratamento de artrite reumatóide e métodos de seu uso
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
IN2015DN00091A (es)
UA103499C2 (ru) Антитело против интерлейкина-17 (ил-17) человека и его применение
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
WO2011002968A3 (en) Polypeptides and method of treatment
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
NZ602548A (en) Oligomer-specific amyloid beta epitope and antibodies
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
WO2012114125A3 (en) Treatment and prevention of malaria
WO2012047732A3 (en) Antibody compositions and methods of use
UA117657C2 (uk) Антитіло до трансглютамінази 2 (tg2)
MY166152A (en) Anti-human xcr1 antibodies
WO2013012811A3 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
NZ601388A (en) Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof